Minilab: Fighting counterfeit medicines

Due to the compact nature of the Minilab (all the devices and resources required for drug testing are contained in two transportable units, each the size of a standard suitcase) and its independence from external energy supplies, the tool is well suited for testing in the field. In this way it helps to bridge capacity gaps on drug quality control in developing countries. Currently around 470 Minilabs have been provided to 78 countries, more than half of which are located in Africa and a third of which are located in Asia. In 2012, Minilab number 500 will be delivered. No comparable product currently exists. The combination of the simple, reliable on-site analysis kit accompanied by a handbook with detailed test instructions is unique. Merck contributes to external research to expand the number of drugs that can be tested, and other ways of optimizing the Minilab on a continual basis. In addition, training is offered to ensure that users are familiar with the test procedures. In 2009, two training courses were conducted in Germany and in Gambia. In 2010, the number of training courses doubled and Merck developed nine new test methods. In 2011, the GPHF developed test methods for an additional five active ingredients and updated the instruction manuals accordingly.